Phase 3 Studies Herald More Options for Metastatic Breast Cancer
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
Diagnosis & Disease Information
BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy
Patients with germline BRCA2 mutations had relatively worse outcomes with endocrine therapy and CDK4/6 inhibitors in the first-line setting and all lines of therapy.
Surgical Staging Affects Some QOL Scores in Early Breast Cancer
An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.
Breast Cancer-Related Lymphedema More Common Among Black Women
A prospective study sought to determine the significance of race on the risk of developing lymphedema and disease severity in women with breast cancer.
Samuraciclib Plus Fulvestrant Demonstrates Antitumor Activity in Advanced Breast Cancer
A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.
ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer
Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.
Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer
Monitoring circulating mutated ESR1 enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Trastuzumab Deruxtecan Improved PFS Across HER2+ Breast Cancer Subgroups
Researchers presented updated findings from the DESTINY-Breast03 trial.
Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
First-Line Ribociclib/Letrozole Effective in Breast Cancer Across Subgroups
An analysis of a cohort of patients from the MONALEESA-2 trial sought to determine the efficacy of adding ribociclib to letrozole for HR+/HER2- breast cancer.
- Loading...
Loading...
Next post in SABCS 2021
Loading... 
Loading...